Home > Publications database > Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts. > print

001     142072
005     20240229105142.0
024 7 _ |2 doi
|a 10.3390/cancers10110451
024 7 _ |2 pmid
|a pmid:30453548
024 7 _ |2 pmc
|a pmc:PMC6265976
024 7 _ |a altmetric:51315853
|2 altmetric
037 _ _ |a DKFZ-2018-02302
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |0 P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9
|a Larribère, Lionel
|b 0
|e First author
245 _ _ |a Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts.
260 _ _ |a Basel
|b MDPI
|c 2018
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1550058817_21064
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a The mechanisms of adaptive and acquired drug resistance in tumors are not completely understood. So far, gene amplifications or mutations, leading to the reactivation of the MAPK or PI3K pathways have been described. In this study, we used two different methods to generate human melanoblasts: (1) via differentiation from induced pluripotent stem cells (iPSCs) and (2) via dedifferentiation from melanocytes. The melanoblast transcriptomes were then compared to the transcriptome of MAPK inhibitor-resistant melanoma cells. We observed that the expression of genes associated with cell cycle control, DNA damage control, metabolism, and cancer was altered in both melanoblast populations and in both adaptive and acquired resistant melanoma samples, compared to drug-sensitive samples. However, genes involved in antigen presentation and cellular movement were only regulated in the melanoblast populations and in the acquired resistant melanoma samples, compared to the drug-sensitive samples. Moreover, melanocyte-derived melanoblasts and adaptive resistant melanoma samples were characterized by different expression levels of certain transcription factors or genes involved in the CDK5 pathway. In conclusion, we show here that in vitro models of human melanoblasts are very important tools to comprehend the expression profiles of drug-resistant melanoma.
536 _ _ |0 G:(DE-HGF)POF3-317
|a 317 - Translational cancer research (POF3-317)
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Kuphal, Silke
|b 1
700 1 _ |0 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
|a Sachpekidis, Christos
|b 2
700 1 _ |0 P:(DE-He78)20c06d682ef2c877e2610cd1984daea5
|a Sachindra, Sachindra
|b 3
|e Collaboration Author
|u dkfz
700 1 _ |0 P:(DE-He78)78e29fad12f1be2fe3d0a8d411f97211
|a Hüser, Laura
|b 4
700 1 _ |0 0000-0001-8147-394X
|a Bosserhoff, Anja
|b 5
700 1 _ |0 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
|a Utikal, Jochen
|b 6
|e Last author
773 _ _ |0 PERI:(DE-600)2527080-1
|a 10.3390/cancers10110451
|g Vol. 10, no. 11, p. 451 -
|n 11
|p 451
|t Cancers
|v 10
|x 2072-6694
|y 2018
909 C O |o oai:inrepo02.dkfz.de:142072
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9
|a Deutsches Krebsforschungszentrum
|b 0
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
|a Deutsches Krebsforschungszentrum
|b 2
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)20c06d682ef2c877e2610cd1984daea5
|a Deutsches Krebsforschungszentrum
|b 3
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)78e29fad12f1be2fe3d0a8d411f97211
|a Deutsches Krebsforschungszentrum
|b 4
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
|a Deutsches Krebsforschungszentrum
|b 6
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF3-317
|1 G:(DE-HGF)POF3-310
|2 G:(DE-HGF)POF3-300
|a DE-HGF
|l Krebsforschung
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b CANCERS : 2017
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
915 _ _ |0 StatID:(DE-HGF)0310
|2 StatID
|a DBCoverage
|b NCBI Molecular Biology Database
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Blind peer review
915 _ _ |0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|a Creative Commons Attribution CC BY (No Version)
|b DOAJ
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b CANCERS : 2017
920 1 _ |0 I:(DE-He78)G300-20160331
|k G300
|l KKE Dermatoonkologie
|x 0
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l KKE Nuklearmedizin
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G300-20160331
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21